Bio-Path Holdings, Inc. (BPTH)
OTCMKTS
· Delayed Price · Currency is USD
0.0552
-0.0098 (-15.08%)
Apr 29, 2026, 1:19 PM EST
Bio-Path Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
579.77K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emmaus Life Sciences | 12.45M |
| Regenerative Medical Technology Group | 5.04M |
| EV Biologics | 9.47M |
| CNBX Pharmaceuticals | 40.64K |
| Sorrento Therapeutics | 64.27M |
| SQZ Biotechnologies Company | 12.12M |
| Halberd | 6.94K |
Bio-Path Holdings News
- 11 months ago - Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 - Newsfile Corp
- 11 months ago - Bio-Path Holdings Provides Clinical and Operational Update - GlobeNewsWire
- 11 months ago - Bio-Path Holdings Transcript: Status Update - Transcripts
- 1 year ago - Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire